Additionally, combining this therapy with other modalitiesholds promise, such as the standard GBM treatment of temozolomide,immune checkpoint inhibitors (e.g., anti-PD-1 or anti-CTLA-4 antibodies), and cancer vaccines, to potentiallyenhance the immune response. The gene discussed is CTLA4; the disease is glioblastoma.